SLC25A19 is a key prognostic marker for hepatocellular carcinoma.

SLC25A19 is a protein that mediates the transport of thiamine pyrophosphate (TPP) across cell membranes, but its significance in cancer remains largely unknown. To address this knowledge gap, we conducted a pan-cancer analysis to investigate the role of SLC25A19 in cancer. To investigate the role of SLC25A19 in cancer, we obtained RNA-seq, survival, and clinicopathological data from 33 cancers in the TCGA database. We performed expression and survival analyses of SLC25A19 across these cancers. Additionally, we explored the diagnostic and prognostic value of SLC25A19 specifically in hepatocellular carcinoma (HCC). To understand the potential role of SLC25A19 in the immune microenvironment of HCC, we also analyzed its expression in relation to immune checkpoint genes. Then we identified the drug most strongly correlated with SLC25A19 expression in HCC. Finally, PCR and Western-Blotting experiments were performed on HCC and its paracancer tissues to verify the expression of SLC25A19. Our analysis revealed that SLC25A19 is overexpressed in hepatocellular carcinoma (HCC) and is associated with poor prognosis. We also found that high expression of SLC25A19 in HCC is associated with high expression of immune checkpoint genes, suggesting a potential role for SLC25A19 in immunotherapy. Furthermore, we identified drugs that are most strongly correlated with SLC25A19 expression in HCC, which could inform treatment decisions for HCC patients. PCR results showed that the expression of SLC25A19 in HCC was significantly up-regulated in 6 pairs of HCC and adjacent normal tissues. Our study can provide a reference for the diagnosis and treatment of HCC.